Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2020

View Archived Issues

Lung changes from Parkinson's disease drug candidates are reversible

Platelets play role in Tylenol toxicity

Hepatic glutaminase 1 targeting reduces steatosis and decreases oxidative stress in NASH models

Chimerix initiates phase II/III study of DSTAT in patients with severe COVID-19

Promising data from compassionate care program of CAP-1002 in critical COVID-19 patients

Phase I data for SNDX-6352 as monotherapy and in combination with durvalumab presented

SVC-112 inhibits tumor growth in HNSCC models

First-in-human data presented for MOv18

Massachusetts General Hospital and collaborators patent SREBF1 inhibitors

Glo Pharma synthesizes new nicotinic acetylcholine receptor antagonists

BAY-2416964: an orally available AhR antagonist for the immunotherapy of advanced solid tumors

New CDK2/cyclin E inhibitors identifies at Incyte

Galecto Biotech presents new galectin-3 inhibitors

Autifony Therapeutics identifies new K(V)3 potassium channel modulators

Reprogramming microglial functional state has therapeutic potential for AD

AZD-9833: an orally available SERD presented by AstraZeneca

Phase II data presented for genolimzumab in peripheral T-cell lymphoma, alveolar soft part sarcoma

First-in-human data presented for TruUCAR-based GC-027

European Commission approves Ruconest to treat HAE attacks in children

Topline data from phase III study of 5- and 10-day dosing regimens of remdesivir in severe COVID-19

Jazz ends enrollment early in phase III trial of defibrotide for prevention of VOD

FDA approves Zejula as first-line maintenance for ovarian cancer regardless of biomarker status

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
SKL-35501 shows broad antitumor activity in solid tumors
BioWorld Science
Neurotensin receptor 1 (NTSR1) is overexpressed in several aggressive solid tumors, including colorectal and pancreatic cancer, making it a promising therapeutic...